Extended Data Fig. 7: Combination of eFT508 and ketogenic diet systemically inhibits pancreatic tumour growth.
From: Remodelling of the translatome controls diet and its impact on tumorigenesis
a. Tumour size, b. Tumour weight, c. Blood BHB levels, and d. Body weight of xenograft mouse models with the human pancreatic cancer cell line AsPC1, treated with chow, eFT508, ketogenic diet or eFT508 and ketogenic diet after the tumours reach 150 mm3 (n = 4 mice). e. Tumour weight (n = 9 or 10 biological independent samples) f. Mouse body weight (n = 5 mice), g. Food intake (n = 5 days), h. Blood glucose levels (n = 5 mice), i. Blood glycerol levels (n = 5 mice), j. Serum fatty acids levels (n = 5 mice), and k. Serum insulin levels (n = 4 or 5 mice) of xenograft mouse models with the human pancreatic cancer cell line T3M4 with different treatment after the tumours reach 150 mm3. l. Relative cell survival of T3M4 cells treated without or with 1 mM BHB in fasting-mimicking medium (no glucose serum-free medium with 100 μM linoleic acid) for 48 h (n = 3 biological independent samples. m. Mouse body weight (n = 5 mice) and n. Represent tumour images of xenograft mouse models with the human pancreatic cancer cell line T3M4, treated with ketogenic diet or eFT508 and ketogenic diet or eFT508 and ketogenic diet with 1% BHB in the drinking water after the tumours reach 150 mm3. All values represent the mean ± SEM; Two-way ANOVA for a, b, c, d, f, h, l, m, One-way ANOVA for e, and two-sided Student’s t test for g, i, j, k.
